Halyard Health, Inc. (NYSE:HYH) – Analysts at KeyCorp issued their FY2019 earnings estimates for Halyard Health in a research report issued to clients and investors on Wednesday. KeyCorp analyst M. Mishan expects that the medical instruments supplier will post earnings per share of $2.28 for the year. KeyCorp has a “Hold” rating on the stock.

Halyard Health (NYSE:HYH) last issued its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.14. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The firm had revenue of $399.20 million for the quarter, compared to the consensus estimate of $399.16 million. During the same quarter in the previous year, the firm earned $0.45 EPS. The company’s quarterly revenue was down .2% compared to the same quarter last year.

WARNING: “Research Analysts Set Expectations for Halyard Health, Inc.’s FY2019 Earnings (HYH)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/20/research-analysts-set-expectations-for-halyard-health-inc-s-fy2019-earnings-hyh.html.

Several other analysts have also recently weighed in on the stock. Zacks Investment Research raised shares of Halyard Health from a “sell” rating to a “hold” rating in a report on Thursday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $45.00 target price on shares of Halyard Health in a report on Thursday, September 21st. BidaskClub upgraded shares of Halyard Health from a “hold” rating to a “buy” rating in a research note on Saturday, August 19th. Deutsche Bank AG increased their price target on shares of Halyard Health from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Stephens upgraded shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research note on Thursday, August 3rd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $42.25.

Shares of Halyard Health (HYH) traded up 1.31% on Friday, hitting $44.01. 289,633 shares of the stock were exchanged. The company’s 50 day moving average is $45.27 and its 200-day moving average is $40.67. The stock has a market cap of $2.06 billion, a PE ratio of 42.32 and a beta of 1.75. Halyard Health has a 52-week low of $31.59 and a 52-week high of $46.63.

Institutional investors have recently made changes to their positions in the business. Riverhead Capital Management LLC increased its stake in Halyard Health by 88.1% in the second quarter. Riverhead Capital Management LLC now owns 3,197 shares of the medical instruments supplier’s stock valued at $126,000 after purchasing an additional 1,497 shares during the last quarter. LS Investment Advisors LLC increased its stake in Halyard Health by 16.1% in the second quarter. LS Investment Advisors LLC now owns 4,017 shares of the medical instruments supplier’s stock valued at $158,000 after purchasing an additional 556 shares during the last quarter. Victory Capital Management Inc. purchased a new position in Halyard Health in the first quarter valued at approximately $153,000. Quotient Investors LLC purchased a new position in Halyard Health in the third quarter valued at approximately $203,000. Finally, Tower Research Capital LLC TRC increased its stake in Halyard Health by 102.5% in the first quarter. Tower Research Capital LLC TRC now owns 4,836 shares of the medical instruments supplier’s stock valued at $184,000 after purchasing an additional 2,448 shares during the last quarter. Institutional investors own 91.02% of the company’s stock.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.